MCF Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.18M | Sell |
12,627
-410
| -3% | -$88.2K | 0.11% | 101 |
|
|
2026
Q1 | $2.84M | Buy |
13,037
+638
| +5% | +$142K | 0.12% | 92 |
|
|
2025
Q4 | $2.83M | Buy |
12,399
+1,576
| +15% | +$359K | 0.16% | 69 |
|
|
2025
Q3 | $2.51M | Buy |
10,823
+1
| +0% | +$204 | 0.15% | 53 |
|
|
2025
Q2 | $2.01M | Buy |
10,822
+26
| +0.2% | +$4.83K | 0.13% | 56 |
|
|
2025
Q1 | $2.26M | Sell |
10,796
-82
| -0.8% | -$15.9K | 0.16% | 52 |
|
|
2024
Q4 | $1.93M | Buy |
10,878
+370
| +4% | +$68K | 0.14% | 54 |
|
|
2024
Q3 | $2.08M | Buy |
10,508
+199
| +2% | +$37.1K | 0.15% | 52 |
|
|
2024
Q2 | $1.77M | Buy |
10,309
+1,459
| +16% | +$242K | 0.13% | 55 |
|
|
2024
Q1 | $1.61M | Sell |
8,850
-30
| -0.3% | -$5.17K | 0.12% | 60 |
|
|
2023
Q4 | $1.38M | Sell |
8,880
-13
| -0.1% | -$1.9K | 0.11% | 67 |
|
|
2023
Q3 | $1.33M | Buy |
8,893
+47
| +0.5% | +$6.9K | 0.12% | 64 |
|
|
2023
Q2 | $1.19M | Buy |
8,846
+950
| +12% | +$139K | 0.11% | 63 |
|
|
2023
Q1 | $1.26M | Buy |
7,896
+230
| +3% | +$35.2K | 0.12% | 57 |
|
|
2022
Q4 | $1.24M | Buy |
7,666
+13
| +0.2% | +$1.99K | 0.13% | 58 |
|
|
2022
Q3 | $1.03M | Buy |
7,653
+8
| +0.1% | +$1.15K | 0.11% | 64 |
|
|
2022
Q2 | $1.17M | Buy |
7,645
+442
| +6% | +$67.5K | 0.12% | 49 |
|
|
2022
Q1 | $1.17M | Buy |
+7,203
| New | +$1.05M | 0.11% | 55 |
|
|
2021
Q4 | – | Sell |
-7,584
| Closed | -$818K | – | 45 |
|
|
2021
Q3 | $818K | Buy |
7,584
+322
| +4% | +$36.8K | 0.08% | 64 |
|
|
2021
Q2 | $818K | Buy |
7,262
+1,023
| +16% | +$115K | 0.08% | 62 |
|
|
2021
Q1 | $675K | Buy |
6,239
+1,053
| +20% | +$113K | 0.08% | 69 |
|
|
2020
Q4 | $556K | Hold |
5,186
| – | – | 0.07% | 70 |
|
|
2020
Q3 | $454K | Buy |
5,186
+266
| +5% | +$25K | 0.06% | 79 |
|
|
2020
Q2 | $483K | Sell |
4,920
-121
| -2% | -$10.7K | 0.07% | 76 |
|
|
2020
Q1 | $384K | Hold |
5,041
| – | – | 0.06% | 82 |
|
|
2019
Q4 | $446K | Hold |
5,041
| – | – | 0.07% | 88 |
|
|
2019
Q3 | $382K | Buy |
5,041
+1,343
| +36% | +$92.1K | 0.06% | 96 |
|
|
2019
Q2 | $269K | Buy |
3,698
+121
| +3% | +$9.51K | 0.04% | 123 |
|
|
2019
Q1 | $288K | Sell |
3,577
-389
| -10% | -$31.8K | 0.05% | 111 |
|
|
2018
Q4 | $366K | Hold |
3,966
| – | – | 0.07% | 84 |
|
|
2018
Q3 | $375K | Sell |
3,966
-3,966
| -50% | -$376K | 0.07% | 88 |
|
|
2018
Q2 | $742K | Buy |
7,932
+3,966
| +100% | +$387K | 0.14% | 51 |
|
|
2018
Q1 | $375K | Hold |
3,966
| – | – | 0.07% | 79 |
|
|
2017
Q4 | $384K | Buy |
3,966
+5
| +0.1% | +$471 | 0.07% | 76 |
|
|
2017
Q3 | $352K | Buy |
3,961
+5
| +0.1% | +$381 | 0.07% | 78 |
|
|
2017
Q2 | $287K | Sell |
3,956
-600
| -13% | -$40.3K | 0.06% | 83 |
|
|
2017
Q1 | $297K | Buy |
4,556
+606
| +15% | +$38.1K | 0.06% | 75 |
|
|
2016
Q4 | $247K | Buy |
3,950
+500
| +14% | +$30.5K | 0.05% | 81 |
|
|
2016
Q3 | $218K | Sell |
3,450
-100
| -3% | -$6.47K | 0.05% | 86 |
|
|
2016
Q2 | $220K | Buy |
3,550
+100
| +3% | +$6.09K | 0.05% | 90 |
|
|
2016
Q1 | $197K | Hold |
3,450
| – | – | 0.05% | 86 |
|
|
2015
Q4 | $204K | Sell |
3,450
-443
| -11% | -$25.5K | 0.05% | 82 |
|
|
2015
Q3 | $212K | Buy |
3,893
+3
| +0.1% | +$195 | 0.05% | 84 |
|
|
2015
Q2 | $261K | Sell |
3,890
-86
| -2% | -$5.61K | 0.07% | 73 |
|
|
2015
Q1 | $233K | Buy |
3,976
+3
| +0.1% | +$181 | 0.06% | 77 |
|
|
2014
Q4 | $260K | Sell |
3,973
-96
| -2% | -$6.05K | 0.07% | 71 |
|
|
2014
Q3 | $209K | Buy |
4,069
+1
| +0% | +$56 | 0.06% | 84 |
|
|
2014
Q2 | $209K | Sell |
4,068
-26
| -0.6% | -$1.36K | 0.07% | 81 |
|
|
2014
Q1 | $210K | Buy |
4,094
+3
| +0.1% | +$152 | 0.07% | 82 |
|
|
2013
Q4 | $210K | Buy |
4,091
+2
| +0% | +$98 | 0.07% | 79 |
|
|
2013
Q3 | $210K | Buy |
4,089
+331
| +9% | +$14.7K | 0.12% | 74 |
|
|
2013
Q2 | $193K | Buy |
+3,758
| New | +$164K | 0.12% | 74 |
|
Other funds holding ABBV
MCF Advisors's ABBV Position: Q2 2026 in Review
MCF Advisors reduced its AbbVie (ABBV) stake by 3.1% in Q2 2026, selling an estimated $88.2K and leaving 12,627 shares worth $3.18M. The position accounts for 0.11% of the portfolio, ranked #101.
MCF Advisors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- MCF Advisors held 12,627 shares of AbbVie worth $3.18M as of Q2 2026.
- MCF Advisors sold 410 AbbVie shares in Q2 2026, an estimated $88.2K.
- AbbVie made up 0.11% of MCF Advisors's portfolio in Q2 2026, its #101 holding.
- MCF Advisors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
- 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.